Effect of Resistance and Aerobic Exercise in CIDP or MMN

Inclusion Criteria: * Age \> 18 and \< 80 years * Diagnosed with definite or probable CIDP or definite or probable MMN fulfilling the European Federation of Neurological Sciences/Peripheral Nerve Society (EFNS/PNS) criteria * Stable maintenance therapy with immunoglobulin (no change of dosage \< 3 months before inclusion) * Duration of CIDP or MMN \> 6 months * Negative result on a pregnancy test (HCG-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study Exclusion Criteria: * Other cause of neuropathy (incl. pressure neuropathy) * Exercise before enrolment (\> 1 hour of exercise per week or \> 4 km bicycling per day) * Walking distance \< 10 meter with or without aid * Diabetes mellitus, severe cardiac or pulmonary disease, malignancies * Known history of adverse reactions to Immunoglobulin A in other products * Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products. * History of malignancies of lymphoid cells and immunodeficiency with lymphoma * Known liver function impairment (ALAT 3 times above upper limit of normal) * Known protein-losing enteropathies or proteinuria. * Known of renal function impairment (creatinine \>120 micromol/L or creatinine \>1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs). * Treatment with any investigational medicinal product within 3 months prior to first infusion of Gammanorm * Known or suspected HIV, Hepatitis Virus C or B infection * Pregnant or nursing women * Planned pregnancy during course of the study